- Exchange: NASDAQ GM
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Specialty Pharmaceuticals
ACADIA Pharmaceuticals Inc
+ Add to WatchlistACAD:US
18.0900 USD 0.3400 1.84%As of 17:20:00 ET on 06/19/2013.
Snapshot for ACADIA Pharmaceuticals Inc (ACAD)
| Open: | 18.4500 | Day's Range: | 17.7500 - 18.6200 | Volume: | 2,583,018 |
|---|---|---|---|---|---|
| Previous Close: | 18.4300 | 52wk Range: | 1.4200 - 20.0900 | 1-Yr Rtn: | +1,082.35% |
Key Statistics for ACAD
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -0.3300 |
| Est. EPS (USD) (12/2013) | -0.3760 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 1,598.52 |
| Shares Outstanding (M) | 88.36 |
| 30 Day Average Volume | 3,839,182 |
| Price/Book (mrq) | 13.6541 |
| Price/Sale (ttm) | 207.0076 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/08/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for ACAD
Company Profile & Key Executives for ACAD
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company is currently working on the treatment of induced dysfunction in Parkinson's disease ,schizophrenia, neuropathic pain and glaucoma.
| Uli HacksellPresident/CEO | Thomas H AasenExec VP/CFO/Treasurer |
| Roger M MillsExec VP:Dev/Chief Medical Ofcr | Glenn F BaityVP/Secy/General Counsel |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
ACAD News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page